- Home
- OMC vs MRNA Comparison
OMC vs MRNA Comparison
Compare OMC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMC | MRNA |
|---|---|---|
| Founded | 1944 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9B | 21.6B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OMC | MRNA |
|---|---|---|
| Price | $71.83 | $65.85 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 12 |
| Target Price | ★ $98.71 | $34.27 |
| AVG Volume (30 Days) | 4.0M | ★ 6.9M |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.20% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 1.35 | N/A |
| Revenue | $17,271,900,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $46.93 | $9.36 |
| Revenue Next Year | $0.48 | $15.43 |
| P/E Ratio | $54.47 | ★ N/A |
| Revenue Growth | ★ 10.09 | 4.29 |
| 52 Week Low | $66.33 | $22.28 |
| 52 Week High | $87.17 | $67.74 |
Technical Indicators
Market Signals| Indicator | OMC | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 69.22 |
| Support Level | $70.32 | $45.69 |
| Resistance Level | $77.12 | N/A |
| Average True Range (ATR) | 2.27 | 4.81 |
| MACD | -0.30 | 1.33 |
| Stochastic Oscillator | 19.59 | 86.50 |
Price Performance
Historical ComparisonAbout OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, ad placement, and public relations. The firm operates globally, providing services in more than 70 countries; it generates more than one half of its revenue in North America and nearly 30% in Europe.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.